<i id='923BFB6A1C'><strike id='923BFB6A1C'><tt id='923BFB6A1C'><pre id='923BFB6A1C'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
ChatGPT in medicine: STAT answers readers' burning questions 
Some medical students still think black patients feel less pain 
Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen 
EU regulator recommends expanding Mounjaro approval to obesity 
George Santos makes 1st court appearance after pleading not guilty to 13 counts 
New research sheds light on how often breast cancer is overdiagnosed 
Affirmative action in medical school literally saved lives 
Parkinson’s finding may lead to tests and, someday, treatments 
New air purifier tech could be key to improving indoor air quality
Some medical students still think black patients feel less pain 
Medical leaders decry Supreme Court decision on affirmative action 
Decentralized clinical trials need collaboration to achieve wider use
George Santos makes 1st court appearance after pleading not guilty to 13 counts 
Richard Slayman had a rejection episode of his pig kidney before leaving hospital
New air purifier tech could be key to improving indoor air quality 
